KR20110028454A - 다발성 골수종 치료법 - Google Patents

다발성 골수종 치료법 Download PDF

Info

Publication number
KR20110028454A
KR20110028454A KR1020107028257A KR20107028257A KR20110028454A KR 20110028454 A KR20110028454 A KR 20110028454A KR 1020107028257 A KR1020107028257 A KR 1020107028257A KR 20107028257 A KR20107028257 A KR 20107028257A KR 20110028454 A KR20110028454 A KR 20110028454A
Authority
KR
South Korea
Prior art keywords
pharmaceutically acceptable
multiple myeloma
myeloma
cells
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020107028257A
Other languages
English (en)
Korean (ko)
Inventor
엔리케 오씨아이오
아타나시오 판디엘라
미구엘 예수스 산
마린 파블로 마누엘 아빌레스
Original Assignee
파르마 마르 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 파르마 마르 에스.에이. filed Critical 파르마 마르 에스.에이.
Publication of KR20110028454A publication Critical patent/KR20110028454A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020107028257A 2008-05-16 2009-05-18 다발성 골수종 치료법 Abandoned KR20110028454A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08380154 2008-05-16
EP08380154.8 2008-05-16

Publications (1)

Publication Number Publication Date
KR20110028454A true KR20110028454A (ko) 2011-03-18

Family

ID=40848780

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107028257A Abandoned KR20110028454A (ko) 2008-05-16 2009-05-18 다발성 골수종 치료법

Country Status (12)

Country Link
US (1) US8435992B2 (enExample)
EP (1) EP2303274A1 (enExample)
JP (1) JP2011520846A (enExample)
KR (1) KR20110028454A (enExample)
CN (1) CN102065865B (enExample)
AU (1) AU2009248039B2 (enExample)
CA (1) CA2724206A1 (enExample)
IL (1) IL209360A (enExample)
MX (1) MX2010012358A (enExample)
NZ (1) NZ589270A (enExample)
RU (1) RU2519750C2 (enExample)
WO (1) WO2009138509A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101471273B1 (ko) * 2013-01-29 2014-12-11 인제대학교 산학협력단 Ｓｏｄ２를 포함하는 보르테조밉 내성 진단용 바이오 마커 조성물 및 이를 이용한 진단 키트

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7919493B2 (en) 2000-04-12 2011-04-05 Pharma Mar, S.A. Anititumoral ecteinascidin derivatives
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
GB0117402D0 (en) 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
EP2307003A2 (en) * 2008-05-16 2011-04-13 Pharma Mar S.A. Combination therapy with pm00104 and another antitumor agent
WO2011048210A1 (en) 2009-10-22 2011-04-28 Pharma Mar, S.A. PDGFR-α AS RESPONSE MARKER FOR PM00104 TREATMENT
KR101718800B1 (ko) 2015-01-21 2017-03-24 주식회사 디알나노 약물 및 ｓｉＲＮＡ의 공동―운반용 나노복합체 및 이의 용도
LT3615544T (lt) 2017-04-27 2023-05-10 Pharma Mar S.A. Priešnavikiniai junginiai
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1074243C (zh) * 1997-09-16 2001-11-07 林禾杰 对虾养殖方法
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY130271A (en) * 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
US6569859B1 (en) 2000-02-22 2003-05-27 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
GB0229793D0 (en) 2002-12-20 2003-01-29 Pharma Mar Sa The gene cluster involved in safracin biosynthesis and its uses for genetic engineering
JP4584245B2 (ja) * 2003-03-12 2010-11-17 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 多発性骨髄腫治療用のアプリジン
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
GB0708691D0 (en) * 2007-05-04 2007-06-13 Pharma Mar Sa Anticancer treatments a

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101471273B1 (ko) * 2013-01-29 2014-12-11 인제대학교 산학협력단 Ｓｏｄ２를 포함하는 보르테조밉 내성 진단용 바이오 마커 조성물 및 이를 이용한 진단 키트

Also Published As

Publication number Publication date
AU2009248039B2 (en) 2014-07-31
NZ589270A (en) 2011-12-22
CA2724206A1 (en) 2009-11-19
RU2519750C2 (ru) 2014-06-20
US8435992B2 (en) 2013-05-07
JP2011520846A (ja) 2011-07-21
RU2010151660A (ru) 2012-06-27
IL209360A0 (en) 2011-01-31
CN102065865A (zh) 2011-05-18
US20110076343A1 (en) 2011-03-31
IL209360A (en) 2015-10-29
AU2009248039A1 (en) 2009-11-19
EP2303274A1 (en) 2011-04-06
WO2009138509A1 (en) 2009-11-19
CN102065865B (zh) 2013-03-20
MX2010012358A (es) 2011-01-25

Similar Documents

Publication Publication Date Title
US8435992B2 (en) Multiple myeloma treatments
US10905701B2 (en) Compositions and methods for inhibiting arginase activity
RU2767664C2 (ru) Комбинированная терапия противоопухолевым алкалоидом
US9526915B2 (en) Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
US20190091217A1 (en) Methods for inhibiting tie-2 kinase useful in the treatment of cancer
AU2019200261A1 (en) Methods for inhibiting tie2 kinase useful in the treatment of cancer
US20100029683A1 (en) Methods for regulating cell mitosis by inhibiting serine/threonine phosphateses
CN106999540B (zh) 组合疗法
WO2018015526A1 (en) Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof
JP2021100982A (ja) Ｍｈｃ−ｉの発現を増加させるためのクルクフェノール化合物
CN112121169A (zh) 用于治疗具有高间质压力的肿瘤受试者的癌症的小分子抑制剂
RU2746705C2 (ru) Комбинация bcl-2 ингибитора и mcl-1 ингибитора, их применения и фармацевтические композиции
US20220016118A1 (en) Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof
KR20260018046A (ko) 이전의 면역 관문 억제제 노출 이력이 있는 대상체의 암 치료 방법
CN121218988A (zh) 治疗未接受bcl2抑制剂的受试者的癌症的方法
WO2021237022A1 (en) Compositions and methods for treating breast cancer
WO2020242910A1 (en) Compositions and methods for treating cancer
CN112999236B (zh) 乌本苷用于治疗脑干胶质瘤的用途
WO2023118062A1 (en) Combination of cisplatin and elimusertib for the treatment of pediatric liver cancers
CN121969366A (zh) 治疗与白介素1β表达降低相关的癌症的方法
AU2024238523A1 (en) Pharmaceutical composition and use thereof
CA3286442A1 (en) Pharmaceutical composition and use thereof
EA039621B1 (ru) Комбинация bcl-2 ингибитора и mcl-1 ингибитора, их применения и фармацевтические композиции
HK1188572B (en) Combination therapy with an antitumor alkaloid

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20101215

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140513

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150911

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20160610

NORF Unpaid initial registration fee
PC1904 Unpaid initial registration fee